RT Journal Article
SR Electronic
T1 Clinical Research on Use of Oxaliplatin in Combination with HCPT, LV and 5FU in a Regimen for Advanced Gastric Cancer
JF Chinese Journal of Clinical Oncology
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 336
OP 341
VO 1
IS 5
A1 Hu, Guoqing
A1 Fu, Qiang
A1 Jin, Maolin
A1 Li, Jie
A1 Pan, Liangxi
A1 Bai, Yuxian
A1 Wang, Huaijin
A1 Zhang, Jianwei
A1 Yu, Ding
YR 2004
UL http://www.cancerbiomed.org/content/1/5/336.abstract
AB OBJECTIVE To observe the effects and adverse reactions of a OXA-HCPT LV/5FU 3 regimen for patients with advanced gastric cancer.METHODS OHLF 3 regimen: OXA 130 mg/m2iv d 1, HCPT 6 mg / m2, iv d 1~5, LV 200 mg/m2iv 2 h followed by a 5FU 400 mg/m2 iv bolus and 5FU 600 mg/m2 iv d 1-3, were given, every 21 days as 1 cycle. Assessment of the tumor was conducted after 3 cycles and the effective cases were confirmed after 4 weeks.RESULTS Among 39 patients, 36 were actually evaluable. Overall response rates (CR + PR) were 50%; the major adverse reactions were mild hematological toxicity, nausea and vomiting and peripheral nerve abnormalities.CONCLUSION The OHLF 3 regimen using OXA and HCPT Is effective and results in mild toxicity when used In combined chemotherapy for advanced gastric cancer.